Grunewald Sonja, Jank Alexander
Department of Dermatology, Venereology, and Allergology, University Hospital Leipzig.
J Dtsch Dermatol Ges. 2015 Apr;13(4):277-89; quiz 290. doi: 10.1111/ddg.12596.
With the increasing use of new, predominantly biologic drugs in dermatology, questions frequently arise in clinical practice as to their safety in women wishing to conceive as well as during pregnancy and lactation. Apart from the Summary of Product Characteristics and the Physician's Desk Reference, reliable information may be obtained from databases such as the one compiled by the Center for Pharmacovigilance and Consultation on Embryonal Toxicology at Charité University Medical Center Berlin (https://www.embryotox.de). Another source of information is researching recent publications, for example via PubMed (http://www.ncbi.nlm.nih.gov/pubmed). This article presents current knowledge from the sources mentioned above, and gives detailed information about the use of new biologic agents in women wishing to conceive as well as during pregnancy and lactation. Drugs reviewed include: infliximab, adalimumab, etanercept, metastatic for psoriasis, vemurafenib, dabrafenib, imatinib, ipilimumab for melanoma, vismodegib for basal cell carcinoma, rituximab for cutaneous lymphoma as well as omalizumab and anakinra used in the treatment of allergies.
随着新型（主要是生物制剂）药物在皮肤科的使用日益增加，临床实践中经常会出现关于这些药物对希望怀孕的女性以及孕期和哺乳期女性安全性的问题。除了药品说明书和《医师案头参考》外，还可以从一些数据库获取可靠信息，比如柏林夏里特大学医学中心胚胎毒理学药物警戒与咨询中心编制的数据库（https://www.embryotox.de）。另一个信息来源是检索近期的出版物，例如通过PubMed（http://www.ncbi.nlm.nih.gov/pubmed）。本文介绍了上述来源的现有知识，并详细说明了新型生物制剂在希望怀孕的女性以及孕期和哺乳期女性中的使用情况。所审查的药物包括：英夫利昔单抗、阿达木单抗、依那西普、用于银屑病的甲氨蝶呤、维莫非尼、达拉非尼、伊马替尼、用于黑色素瘤的伊匹木单抗、用于基底细胞癌的维莫德吉、用于皮肤淋巴瘤的利妥昔单抗以及用于治疗过敏的奥马珠单抗和阿那白滞素。
